Top Story

rVIII-SingleChain appears safe, effective for severe hemophilia A

August 24, 2016

The novel therapy rVIII-SingleChain demonstrated hemostatic efficacy in surgery and controlled bleeding events in patients with severe hemophilia A, according to clinical study results published in Blood.

The therapy also conferred a low annualized bleeding rate in patients on prophylaxis and appeared well tolerated.

In the Journals

TAVR survival rate similar in patients with aortic stenosis, cancer vs. no cancer

August 23, 2016
Patients with severe aortic stenosis and active cancer who undergo transcatheter aortic valve replacement had comparable survival rates compared with patients with
In the Journals Plus

Plasma analysis shows promise for NSCLC T790M genotyping

August 23, 2016
Patients with T790M–positive advanced non–small cell lung cancer demonstrated similar outcomes with osimertinib whether the T790M mutation was detected…
FDA News

FDA grants priority review to rucaparib for advanced BRCA–mutated ovarian cancer

August 23, 2016
The FDA granted priority review to rucaparib for the treatment of advanced ovarian cancer in patients with germline or somatic BRCA–mutated tumors. The…
In the Journals Plus

Corticosteroids, immune globulin induce similar platelet count responses for ITP during pregnancy

August 23, 2016
Pregnant women with immune thrombocytopenia had similar maternal platelet count responses whether treated with IV immune globulin or corticosteroids, according to the…
More News Headlines »

The Patient with Non-Small Cell Lung Cancer

No commercial support for this activity.

The management of non-small cell lung cancer (NSCLC) has evolved in the past decade, as advances are made in diagnosis…
More »
Meeting News Coverage

VIDEO: Crenolanib, venetoclax demonstrate ‘very exciting’ results in AML

August 21, 2016
More »
Discoveries from ASCO 2016: Breast Cancer

Discoveries from ASCO 2016: Breast Cancer


Management of Multiple Myeloma: Using Emerging Therapies with ASCT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.

Multiple myeloma management has undergone profound changes in the past few decades, this is largely due to advances in…
More »
Current Issues
View the Current Issue
HemOnc Today